Literature DB >> 17675723

Breaking the silence: what homeless 18- to 24-year-olds say about HIV vaccine trials.

Deborah Koniak-Griffin1, Adeline Nyamathi, Louise Tallen, Evelyn González-Figueroa, Ernestina Dominick.   

Abstract

Development of a global HIV vaccine will require enrollment of a large number of adults and adolescents in clinical trials. Involvement of homeless young adults in these trials will be particularly important because they often practice high-risk behaviors and are disproportionately infected by HIV. This qualitative study explores factors that might affect future participation of homeless 18- to 24-year-olds of diverse racial/ethnic backgrounds in HIV vaccine trials (HIVVTs). Twenty males and females attended focus groups. Participants expressed concern about seroconversion, the trustworthiness of the researchers and/or government agencies conducting trials, vaccine side effects, and possible negative behavior change as a result of being vaccinated. Understanding the personal perspectives of high-risk young adults will enable researchers to tailor protocols to their individual needs and cultural values and, in so doing, potentially enhance willingness to participate in HIVVTs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17675723     DOI: 10.1353/hpu.2007.0061

Source DB:  PubMed          Journal:  J Health Care Poor Underserved        ISSN: 1049-2089


  3 in total

1.  Relationship-level analysis of drug users' anticipated changes in risk behavior following HIV vaccination.

Authors:  April M Young; Daniel S Halgin; Jennifer R Havens
Journal:  AIDS Care       Date:  2015-03-02

2.  A Practical Framework for Navigating Ethical Challenges in Collaborative Community Research.

Authors:  Joyce Hunter; David Lounsbury; Bruce Rapkin; Robert Remien
Journal:  Glob J Community Psychol Pract       Date:  2011-01

3.  Will HIV vaccination reshape HIV risk behavior networks? A social network analysis of drug users' anticipated risk compensation.

Authors:  April M Young; Daniel S Halgin; Ralph J DiClemente; Claire E Sterk; Jennifer R Havens
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.